ReviewCurrent gastroenterology reports2016
Practical Approaches to "Top-Down" Therapies for Crohn's Disease.
Review in Current gastroenterology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05720221 (Adalimumab Versus Ustekinumab in Management of Inflammatory Bowel Disease in Egyptian Patients), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adalimumab Versus Ustekinumab in Management of Inflammatory Bowel Disease in Egyptian Patients
Who cites it
5 citing papers in PubMed, 14 citations in OpenAlex.
- Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease.Journal of managed care & specialty pharmacy · 2022Article
- Correlation between ultrasound consolidated score and simple endoscopic score for determining the activity of Crohn's disease.The British journal of radiology · 2020Article
- Integrated omics profiling of dextran sodium sulfate-induced colitic mice supplemented with Wolfberry (NPJ science of food · 2020Article
- Novel Approaches to Ileocolic and Perianal Fistulising Crohn's Disease.Gastroenterology research and practice · 2018Review
- Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease?Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) is a chronic, progressive, and disabling disease that leads in most cases to the development of bowel damage presenting as a fistula, abscess, or stricture. For years, therapy for Crohn's disease has been based on a "step-up" approach, in which anti-TNF agents are administered after the failure of steroids and immunosuppressants. However, recent studies have suggested that early introduction of anti-TNF agents combined with immunosuppressants can modify the natural history of the disease. Patients who could benefit more of this "top-down" strategy would be those at elevated risk of a complicated or severe inflammatory bowel disease or with factors that can predict an aggressive disease course. Therefore, the management of a patient with CD should be personalized, taking into account the patient's specific characteristics and comorbidities, disease activity, site and behavior of the disease, and predictable factors of poor prognosis. A balance between medication and potential adverse effects should be achieved, trying to avoid under or overtreatment, always discussing the different therapeutic options with the patient. The natural history of ulcerative colitis differs from CD and, to date, there is not much scientific evidence on the use of early combined immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.